InterCure Finalizes $5M Private Placement at $2.918/Unit with CEO Participation Pending Approval
INCR sits 72% above its 52-week low of $3.4 on elevated volume (3.7× avg).
Summary
InterCure finalized a $5 million private placement of 1.58 million units at $2.918 each, with CEO Rabinovich's $2 million participation pending shareholder approval. Proceeds fund working capital and the Nir Oz facility rehabilitation.
Key Events · Financing and Capital Events · INCR
-
Private Placement Completed
Issued 1,579,028 units at $2.918 per unit on August 25, 2026, raising $5 million in gross proceeds (excluding CEO Rabinovich's ~$2 million).
-
Warrant Terms
Each unit includes one five-year warrant exercisable at $1.59 per share (NIS 4.125), potentially adding 1.58 million shares if fully exercised.
-
CEO Participation Pending Approval
CEO Alexander Rabinovich, beneficial owner of ~26% of outstanding shares, is investing ~$2 million but requires shareholder approval; all other investors closed without approval.
-
Use of Proceeds
Funds earmarked for working capital and rehabilitation of the Nir Oz facility of wholly owned subsidiary Canndoc Ltd.
Analysis · INCR · Life Sciences
InterCure completed a $5 million private placement on August 25, 2026, issuing 1,579,028 units at $2.918 each — each unit comprising one ordinary share and one five-year warrant exercisable at $1.59. CEO Alexander Rabinovich, who owns approximately 26% of outstanding shares, is participating for roughly $2 million, but his portion requires shareholder approval. The pricing is notable: at $2.918 per unit, the shares are being issued at a significant discount to the current $5.85 market price, though the reverse split on August 24 complicates direct comparison. The capital funds working capital needs and rehabilitation of the Nir Oz facility, extending the company's runway following its recent $77 million war-damages settlement.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INCR was trading at $5.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $69.7M. The 52-week trading range was $3.40 to $8.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.